Improving quality of life in DME patients

Article

Intravitreal ranibizumab (IVR) has been found to improve vision related quality of life in diabetic macular oedema (DME) patients, notes a study recently published in the Journal of Diabetes and Its Complications.

Intravitreal ranibizumab  (IVR) has been found to improve vision related quality of life in diabetic macular oedema (DME) patients, notes a study recently published in the Journal of Diabetes and Its Complications.

The prospective study, performed by Dr Elif Turkoglu et al. of Akdeniz University, Department of Ophthalmology, Antalya, Turkey, compared the changes in vision related quality of life in DME patients either undergoing treatment with IVR or focal/grid laser. Seventy patients were included in the study group who all had clinically significant macular oedema (CSME). Patients were randomly assigned into two groups, either receiving IVR or laser treatment, and treatments were repeated when necessary.

Both demographic and clinical findings were similar for both groups before treatment. However, the improvements in distance and near visual acuities and the reduction in central retinal thickness (CRT) were greater in the IVR group compared with the laser group.

For vision related quality of life, both groups saw improvement from baseline to 6 months but the improvement in the overall composite score for the IVR group was 6.3 points and only 3 points for the laser group.

 

As a result of their findings, the researchers report that IVR is a useful treatment for improvement of visual acuity, CRT and vision related quality of life and offers a better outcome for patients over laser treatment. Further, they claim that these patient-reported outcomes could have an important role in DME treatment choice.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.